EUVIMEDEUVIMED entdecken
Crossref

Validated LC–MS/MS Method for the Quantitative Determination and Pharmacokinetic Profiling of Fedratinib (TG101348), an Oral JAK2 Inhibitor, in CD1 Mice Plasma

Rajesh Kumar Boggavarapu, Vishwottam Kandikere, Jithendra Chimakurthy iD

Biomedical Chromatography · 2026

DOI: 10.1002/bmc.70285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Rajesh Kumar Boggavarapu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research, Guntur, Andhra Pradesh, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Janus Kinase 2, Sulfonamides, Pyrrolidines. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fedratinib, a selective Janus kinase 2 (JAK2) inhibitor approved by the FDA for the treatment of myeloproliferative neoplasms, particularly myelofibrosis (MF), has clinical relevance. Despite this, no liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been reported for its quantification in biological matrices. This study aimed to develop and validate an LC–MS/MS method for quantifying fedratinib in mice plasma and assessing its pharmacokinetics. The method employed a Sciex 4500 triple quadrupole mass spectrometer with a Shimadzu LC system in positive ionization mode. Chromatographic separation was achieved using a Phenomenex Kinetex C18 column (2.1 × 50 mm, 5.0 μm) with a gradient mobile phase of 5 mM ammonium formate in 0.1% formic acid and acetonitrile at a flow rate of 0.8 mL/min. Telmisartan was used as the internal standard (IS). The method was validated in accordance with USFDA M10 bioanalytical guidelines. Fedratinib and IS were detected at m/z 525.5 → 468.9 and m/z 515.2 → 276.0, respectively. The assay demonstrated excellent sensitivity (LLOQ: 0.5 ng/mL), linearity (0.5 to 1000.0 ng/mL, r 2 = 0.99), and accuracy (95.80–104.52%). Stability studies confirmed the analyte's integrity across multiple freeze–thaw cycles. The developed LC–MS/MS method is selective, sensitive, fully validated, and was successfully applied to pharmacokinetic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryJanus Kinase 2SulfonamidesPyrrolidinesAnimalsMiceChromatography, LiquidReproducibility of ResultsLinear ModelsDrug StabilityMaleLimit of DetectionSensitivity and SpecificityAdministration, OralLiquid Chromatography-Mass SpectrometryBenzenesulfonamides

Stichwörter der Autor:innen

FedratinibJAK2 inhibitorLC–MS/MSTG101348Telmisartanmyelofibrosistumor

Substanzen

fedratinibJanus Kinase 2SulfonamidesPyrrolidinesBenzenesulfonamides

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research, Guntur, Andhra Pradesh, India.
  • Division of Biology, Syngene International Limited, Bangalore, Karnataka, India.

ORCID-Profile: Jithendra Chimakurthy

Zitieren

APA

Boggavarapu, R. K., Kandikere, V., & Chimakurthy, J. (2026). Validated LC–MS/MS Method for the Quantitative Determination and Pharmacokinetic Profiling of Fedratinib (TG101348), an Oral JAK2 Inhibitor, in CD1 Mice Plasma. Biomedical Chromatography. https://doi.org/10.1002/bmc.70285

Vancouver

Boggavarapu RK, Kandikere V, Chimakurthy J. Validated LC–MS/MS Method for the Quantitative Determination and Pharmacokinetic Profiling of Fedratinib (TG101348), an Oral JAK2 Inhibitor, in CD1 Mice Plasma. Biomedical Chromatography. 2026. doi:10.1002/bmc.70285

BibTeX
@article{Boggavarapu2026,
  author = {Boggavarapu, Rajesh Kumar and Kandikere, Vishwottam and Chimakurthy, Jithendra},
  title = {Validated LC–MS/MS Method for the Quantitative Determination and Pharmacokinetic Profiling of Fedratinib (TG101348), an Oral JAK2 Inhibitor, in CD1 Mice Plasma},
  journal = {Biomedical Chromatography},
  year = {2026},
  doi = {10.1002/bmc.70285}
}
Kostenlos starten →